The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613000845730
Ethics application status
Approved
Date submitted
12/05/2013
Date registered
1/08/2013
Date last updated
20/03/2017
Type of registration
Retrospectively registered

Titles & IDs
Public title
Using Positron Emission Tomography (PET) imaging to measure kidney function
Scientific title
In adults having Cr-51 EDTA glomerular filtration rate (GFR) estimation, what is the agreement with Ga-68 EDTA PET/CT?
Secondary ID [1] 282907 0
Nil Known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Kidney function 289127 0
Condition category
Condition code
Renal and Urogenital 289467 289467 0 0
Kidney disease
Cancer 289468 289468 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
1. Ga-68 EDTA PET/CT scan (15-20 minute duration)
2. Small blood sample taken at several time points (2, 3, 4hrs) to count radioactivity which is used to determine renal function
Intervention code [1] 287143 0
Diagnosis / Prognosis
Comparator / control treatment
Conventional Cr-51 EDTA GFR plasma clearance. The same blood samples taken to count Ga-68 radioactivity, is also used to count Cr-51, so both can be directly compared.
Control group
Active

Outcomes
Primary outcome [1] 289569 0
Compare Ga-68 EDTA PET/CT calculated glomerular filtration rate (GFR) with results of Cr-51 EDTA. The GFR is calculated from the blood samples taken, and also from the PET scan.
Timepoint [1] 289569 0
Single time-point
Secondary outcome [1] 302749 0
Correlate assessment of differential or regional renal function with results of prior renal imaging. The contribution of each kidney to overall kidney function can be calculated from the PET scan. This will be compared to any prior tests that been performed for this purpose, usually a Tc-99m DMSA planar or SPECT/CT scan.
Timepoint [1] 302749 0
Single time-point

Eligibility
Key inclusion criteria
- Patient referred for Cr-51 EDTA study at our institution
- Age >= 18 years
- Written informed consent has been provided. One of the investigators will personally meet each candidate to explain the study and obtain written informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participant is not able to tolerate supine position on PET/CT bed for the duration of the PET/CT acquisitions, is not cooperative, or needs continuous nursing (e.g. patient from Intensive Care Unit).
- Pregnancy
- Breast-feeding

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 982 0
Peter MacCallum Cancer Institute - East Melbourne

Funding & Sponsors
Funding source category [1] 287273 0
Self funded/Unfunded
Name [1] 287273 0
Physician Sponsored
Country [1] 287273 0
Australia
Primary sponsor type
Individual
Name
Dr Michael Hofman
Address
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Country
Australia
Secondary sponsor category [1] 286026 0
Hospital
Name [1] 286026 0
Peter MacCallum Cancer Centre
Address [1] 286026 0
St Andrews Place
East Melbourne VIC 3002
Country [1] 286026 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 289253 0
Peter MacCallum Cancer Centre Ethics Committee
Ethics committee address [1] 289253 0
Ethics committee country [1] 289253 0
Australia
Date submitted for ethics approval [1] 289253 0
Approval date [1] 289253 0
04/04/2012
Ethics approval number [1] 289253 0
12/07

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 39990 0
Dr Michael Hofman
Address 39990 0
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Country 39990 0
Australia
Phone 39990 0
613 9656 1852
Fax 39990 0
Email 39990 0
Contact person for public queries
Name 39991 0
Michael Hofman
Address 39991 0
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Country 39991 0
Australia
Phone 39991 0
613 9656 1852
Fax 39991 0
Email 39991 0
Contact person for scientific queries
Name 39992 0
Michael Hofman
Address 39992 0
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Country 39992 0
Australia
Phone 39992 0
613 9656 1852
Fax 39992 0
Email 39992 0

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Embase68Ga-EDTA PET/CT imaging and plasma clearance for glomerular filtration rate quantification: Comparison to conventional 51Cr-EDTA.2015https://dx.doi.org/10.2967/jnumed.114.147843
N.B. These documents automatically identified may not have been verified by the study sponsor.